Advertisement
Decision Resources also finds that both bapineuzumab and Eli Lilly'sLY-2062430 will quickly become blockbusters shortly after their launch due totheir efficacy and high price point. The widespread use of these agents willdepend, in part, on their safety and the complementary use of new diagnosistechniques that would permit patients to be diagnosed in the early stages ofthe disease, when disease-modifying therapies provide the greatest therapeuticbenefit.
Advertisement
"We await Phase III results of the bapineuzumab trials with greatinterest, both in terms of the drug's safety profile, but also its efficacy inAlzheimer's disease patients carrying the ApoEe4 gene (which is a risk factorin Alzheimer's disease) compared with non-ApoEe4 gene carriers," states AndreaWitt, Ph.D., director at Decision Resources. "Should efficacy prove poor inApoEe4 gene carriers, patients will be faced with the difficult decision ofwhether they would want to know whether they carry this gene. Nevertheless,even if bapineuzumab benefits only the non-ApoEe4 gene carriers-a prospectivepopulation of 40 to 70 percent of Alzheimer's disease patients-bapineuzumabstands to reap considerable profits in the Alzheimer's disease market."
Two new Decision Resources Alzheimer's disease reports-the Pharmacorreport entitled Alzheimer's Disease and Brands & Strategies: Alzheimer'sDisease-have been updated to include new data and analysis on how theAlzheimer's disease market is impacted by the failure of Flurizan. Some of thekey questions answered in the reports include:
About Decision Resources
Decision Resources (www.DecisionResources.com) is a world leader inresearch publications, advisory services and consulting designed to helpclients shape strategy, allocate resources and master their chosen markets.Decision Resources is a Decision Resources, Inc. company.-- How does the failure of Flurizan impact the current Alzheimer's disease market competitors, and which companies benefit the most? -- How will the absence of Flurizan change the performance of emerging therapies? Will the overall Alzheimer's disease market expand or contract? -- How will Lundbeck weather the failure of Flurizan? -- What impact will Flurizan's discontinuation have on the Alzheimer's disease market over the 2007-2017 time period? -- Which drug stands most to gain from Flurizan's discontinuation?
SOURCE Decision Resources
